Abstract
Introduction
Insulin resistance (IR) syndrome is composed of risk factors for cardiovascular disease, including IR with hyperinsulinemia, atherogenic dyslipidemia, hypertension, abdominal obesity, and impaired hemostasis. Patients with type 2 diabetes mellitus (DM) in whom IR is the core problem frequently manifest multiple risk factors for cardiovascular morbidity and mortality. Hypertension is a common problem in diabetic patients [1] [2] [3] [4] . Antihypertensive agents that can ameliorate IR may help to reduce the risk of cardiovascular disease [5] . Class differences in the effects of antihypertensives on metabolic indices may therefore be an important consideration when choosing treatment for patients who exhibit these characteristics. Experience from clinical trials suggests that drugs that target the reninangiotensin system may have metabolic advantages over drugs such as beta-blockers and diuretics, but this conclusion has not been proved definitively [6] .
Most of the clinical studies evaluating the effect of angiotensin converting enzyme inhibitors (ACEI) on insulin sensitivity reported enhanced insulin sensitivity. However a limited number of clinical investigations have demonstrated ACEIs to be metabolically neutral in healthy and in hypertensive nondiabetic or type 2 diabetic subjects [4, 5] . One possible explanation for these neutral findings might be the fact that the baseline insulin sensitivity of the subjects in these investigations was either normal or slightly depressed [7, 8] . It was shown that as the number of the components of the metabolic syndrome increases, the degree of IR increases [9] .
Trandolapril is a long acting ACEI [10] . Although it was shown to improve IR in insulin resistant obese Zucker or spontaneously hypertensive rat studies [11, 12] , many clinical studies showed that trandolapril has a neutral effect on IR in hypertensive patients with type 2 DM [13] [14] [15] . As trandolapril is a lipophylic agent [10] , by acting on adipose tissue, it might be more efficient in obese subjects by tissue ACE inhibition. Although the antihypertensive effectiveness of trandolapril has been detailly investigated, its' effects on IR, glucose and lipid metabolisms in humans are quite obscure. This study was aimed to compare these effects in type 2 diabetic and nondiabetic hypertensive patients with different degrees of IR and investigate the importance of IR level in ACEI response concerning glucose and lipid metabolisms. 
Material and Methods

Patient Selection and Study Design
A prospective, open-labelled observational study was conducted in consecutive hypertensive type 2 diabetic and nondiabetic outpatients who were followed up in our diabetes and hypertension outpatient clinics. Informed consent was obtained from all participants, and the study was performed in accordance with the Declaration of Helsinki and with the approval of the local ethics committee. 
Measurements
Trandolapril was given once daily in the morning between 08:00 and 09:00 for 12 weeks.
Blood Pressure (BP) measurements were obtained from each patient's right arm in seated position by using a standard mercury sphigmomanometer. Measurements were taken in the morning before daily drug intake (ie, 24 h after dosing, at trough) and after the subject rested 
Statistical Analysis
Clinical and laboratory data were expressed as mean  SEM. By taking variability skewness (a3) and curtosis (a4) 
Results
All patients enrolled in the trial completed the trandolapril treatment except two female patients -one from each group-who could not tolerate the drug due to severe headache and symptomatic hypotension. The characteristic features of both groups were similar (p>0.05, to the trandolapril treatment with a sensitivity of 75% and a specificity of 65% (area under the ROC curve= 0.700, Fig. 1 ), but not for the pretreatment insulin level. Baseline and after 12 weeks treatment, lipid parameters were similar in both groups. Mean HDL, Apo A1 and Lp(a) values were increased and Apo B decreased in the nondiabetic group after trandolapril treatment. There were increments in apo A1 and decrements in Lp(a) levels in the diabetic group (Table 3) . There was only a significant difference between percentage changes of Lp(a) in nondiabetic and diabetic patients (5.8% vs -11.5%, p>0.01). There was no 
Discussion
In the present study, after 12 weeks of treatment, trandolapril was found to be improving insulin sensitivity in type 2 diabetic hypertensive patients, despite no effect on IR in nondiabetic ones and lowers BP significantly in both groups.
In a hospital-based study performed in our country, mean value for HOMA-IR was found to be 2.24 in healthy subjects, 3.13 for hypertensives and 5.51 for diabetic patients [18] . Mean HOMA-IR level of our diabetic patients were higher than those of nondiabetics (9.0 vs 5.6) and both higher than those of the groups mentioned above.
The potential mechanisms of metabolic actions of ACEIs appear to represent a class effect, which are inhibition of angiotensin II formation that may have glycogenolytic and gluconeogenic properties, inhibition of bradykinin degradation, vasodilatation of insulinsensitive tissues or decrease in circulating catecholamines [5, 14] . However, no increase in insulin sensitivity was found in healthy volunteers or in hypertensive subjects with essentially normal insulin sensitivity following administration of the ACEIs, lisinopril [7] or enalapril [8] for 4 weeks. These negative findings might be due to either normal [7] or only slightly depressed [8] baseline insulin sensitivity of the subjects in these investigations. Another potential explanation may be the design of the studies in which the action of the ACEI was measured 24 h after the last administration [5] .
Trandolapril is a new generation nonsulphydryl, lipophylic ACEI with high tissue penetration and long elimination half life [10] . In experimental studies, acute and/or chronic administration of trandolapril improved insulin stimulated glucose transport in skeletal muscle in IR obese Zucker or spontaneously hypertensive rats compared to lean and normotensive controls [11, 12] . Trandolapril was shown to enhance skeletal muscle insulin action and GLUT-4 protein levels in insulin resistant obese rats and it had no effect in insulin sensitive lean rat muscle [19] . In contrast to experimental studies most of the clinical studies conducted indicated that trandolapril has a neutral effect on IR [13] [14] [15] 20] . Only in one clinical study conducted in overweight hypertensive patients with low grade IR trandolapril improved insulin sensitivity moderately compared to nifedipine in the absence of severely obese and diabetic individuals [21] . Despite these conflicting results, we observed a significant decrement in IR in diabetic patients, but not in nondiabetic hypertensives. This interesting result may be due to the fact that IR was more prominent in our diabetic hypertensive patients.
The mean levels of HOMA-IR and fasting insulin were significantly higher in this group. A high HOMA-IR (≥2.56) and fasting insulin concentration (≥9.98 µIU/mL) were found to be independent risk factors of the metabolic syndrome by multiple regression analysis after adjusting for age, gender and BMI [9] . A ≥4.67 pretreatment HOMA-IR value was the main determinant of the IR decrement effect of trandolapril in our study, there was no such a value for pretreatment insulin level (Figure 1 ). The changes in BP and BMI after trandolapril treatment could affect IR in our study population. MNT and exercise programmes could be considered in part a reason for the differences in weight change and IR. Infact, same programmes were given to both groups with similar percentages of carbohydrates, proteins and lipids in total daily calories except MNT without pure glucose for diabetics. No correlation was found between changes in BP and insulin sensitivity and a significant decrement was obtained in the BMI only in the diabetic patients. Multivariate model showed that changes in BP and BMI did not affect the decrease in HOMA-IR in all patients. ACEIs may affect insulin sensitivity, in part, by modulating some cytokines and inflammatory markers [22] [23] [24] . Adiponectin is a cytokine that has protective effect against cardiovascular diseases. It's level decreases in the presence of IR, hypertension and type 2 diabetes. Trandolapril was found to be increasing adiponectin levels alone or in combination with verapamil [22] . Resistin is another cytokine that has strong positive correlation with IR and vascular inflammation. Type 2 diabetic and hypertensive subjects are known to have higher plasma resistin levels. Trandolapril was found to be decreasing resistin levels alone or in combination with verapamil [23] . TNF-alpha levels were reported to be higher in obese type 2 diabetic patients with IR compared to ones without IR and controls [25] . It's known that TNF-alpha increases resistin production and has inverse relation with adiponectin [23] . Lipophylicity of trandolapril could improve insulin mediated glucose utilization in adipose tissue via changes in adiponectin, resistin and/ or TNF-alpha, which are known to be a involved in obesity related IR.
Some authors demonstrated no change in insulin sensitivity after 18 weeks or 3 months of treatment with captopril in hypertensive nondiabetic or type 2 diabetic patients, despite a reduction in patients' weight of 1.5 or 1.1 kg, respectively [26, 27] . Obese ratios and baseline BMI values of nondiabetic and diabetic patients were comparable. We found no significant correlation between the changes in HOMA-IR and weight at the end of 12 weeks of trandolapril treatment in the diabetic patients.
ACEIs might have an effect on glycemic control. CAPPP and HOPE are two large intervention trials that have pointed out the fact that long-term ACEI treatment result in a lower risk of developing type 2 DM in subjects with different risks of cardiovascular disease [28, 29] . Besides, it was reported that patients with metabolic syndrome may be at lower risk of diabetes when using ACEI containing fixed dose combination antihypertensive treatments [30] . The results of UKPDS showed that captopril provided a more favourable A1C profile and a lesser reliance on antidiabetic drugs in type 2 diabetic patients compared to treatment with atenolol [31] . Contrary to these favourable effects on glucose metabolism, verapamil SR plus trandolapril was shown to lack an effect on glycemic control in a different study [32] . In our study, change of A1C in diabetic patients was significant when compared with nondiabetics after trandolapril treatment. But, decrements in serum glucose and A1C levels in diabetics were insignificant although HOMA-IR improved. Furthermore, multivariate model showed that changes in A1C did not affect the decrease in HOMA-IR in all patients.
Hyperinsulinemia becomes a risk factor for macrovascular complications and coronary artery disease by increasing VLDL, IDL and LDL levels and decreasing HDL level. ACEIs are generally known to be neutral when lipid metabolism is considered [33] . Fosinopril was shown to decrease Lp(a) levels 23% compared to the basal level while the decrement in the placebo group was 12% [13] . On the other hand, trandolapril was shown to be neutral concerning lipid metabolism [34] . In our study trandolapril increased apo A1 in both groups and decreased Lp(a) only in the diabetic patients. Lp(a) is a cardiovascular risk factor genetically committed, but several nongenetic factors may affect it's plasma concentration.
The improvement of IR may modify Lp(a) levels in our diabetic patients. But, our data was limited to clarify this observation.
In conclusion, trandolapril improved insulin sensitivity better in type 2 diabetic hypertensive patients with moderate degree of IR in comparison with the ones with low grade IR, being independent of its hemodynamic action. ACEIs can have some theoretical clinical advantages beyond BP lowering in the antihypertensive treatment of the subjects at greater risk for complications due to IR. Prospective clinical studies with longer follow-up and larger sample sizes are warranted to evaluate the use of trandolapril to predict the IR response in patients with high IR.
